ViMRT
}  
 
Home   
< Docs   

 SARS_CoV_2 mutation literature information.


  Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies.
 PMID: 34642465       2021       Scientific reports
Abstract: The main findings from this study show that, compared to the wild-type SARS-CoV-2 spike protein, mutations E484A/G/K/Q/R/V, Q493K/L/R, S494A/P/R, L452R and F490S are predicted to be markedly resistant to neutralization by LY-CoV555, while mutations K417E/N/T, D420A/G/N, N460I/K/S/T, T415P, and Y489C/S are predicted to confer LY-CoV016 escaping advantage to the viral protein.
Result: Surprisingly, however, the computational mutagenesis data for all circulating viral mutations at these two  PMID: 35140714       2021       Frontiers in immunology
Discussion: N440K and K444Q can escape against REGN10987, while K417N, N460T, and A475V can successfully escape against LY-CoV016 antibody (AbCellera), currently approved by the FDA for COVID-19 therapy.



Browser Board

 Co-occurred Entities




   Filtrator